Multimodal Evoked Potentials as Candidate Prognostic and Response Biomarkers in Clinical Trials of Multiple Sclerosis.
Journal
Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society
ISSN: 1537-1603
Titre abrégé: J Clin Neurophysiol
Pays: United States
ID NLM: 8506708
Informations de publication
Date de publication:
01 May 2021
01 May 2021
Historique:
entrez:
7
5
2021
pubmed:
8
5
2021
medline:
23
6
2021
Statut:
ppublish
Résumé
Evoked potentials (EPs) measure quantitatively and objectively the alterations of central signal propagation in multiple sclerosis and have long been used for diagnosis. More recently, their utility for prognosis has been demonstrated in several studies, summarizing multiple EP modalities in a single score. In particular, visual, somatosensory, and motor EPs are useful because of their sensitivity to pathology in the frequently affected optic nerve, somatosensory tract, and pyramidal system. Quantitative EP scores show higher sensitivity to change than clinical assessment and may be used to monitor disease progression. Visual EP and the visual system have served as a model to study remyelinating therapies in the setting of acute and chronic optic neuritis. This review presents rationale and evidence for using multimodal EP as prognostic and response biomarkers in clinical trials, targeting remyelination or halting disease progression in multiple sclerosis.
Identifiants
pubmed: 33958567
doi: 10.1097/WNP.0000000000000723
pii: 00004691-202105000-00004
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
171-180Informations de copyright
Copyright © 2021 by the American Clinical Neurophysiology Society.
Références
Baker JB, Larson SJ, Sances A, White PT. Evoked potentials as an aid to the diagnosis of multiple sclerosis. Neurology 1968;18:286.
Halliday AM, McDonald WI, Mushin J. Delayed visual evoked response in optic neuritis. Lancet 1972;1:982–985.
Robinson K, Rudge P. Abnormalities of the auditory evoked potentials in patients with multiple sclerosis. Brain 1977;100(pt 1):19–40.
Hess CW, Mills KR, Murray NM. Measurement of central motor conduction in multiple sclerosis by magnetic brain stimulation. Lancet 1986;2:355–358.
Eleftheriadou A, Deftereos SN, Zarikas V, et al. The diagnostic value of earlier and later components of vestibular evoked myogenic potentials (VEMP) in multiple sclerosis. J Vestib Res 2009;19:59–66.
Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227–231.
Thompson AJ, Montalban X, Barkhof F, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 2000;6:831–835.
McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121–127.
Solomon AJ, Bourdette DN, Cross AH, et al. The contemporary spectrum of multiple sclerosis misdiagnosis: a multicenter study. Neurology 2016;87:1393–1399.
Calabrese M, Gasperini C, Tortorella C, et al. “Better explanations” in multiple sclerosis diagnostic workup: a 3-year longitudinal study. Neurology 2019;92:e2527–e2537.
McDonald WI, Sears TA. Effect of demyelination on conduction in the central nervous system. Nature 1969;221:182–183.
McDonald WI. Pathophysiology of conduction in central nerve fibres. In: Desmedt JE. ed. Visual evoked potentials in man: New developments. Oxford, United Kingdom: Clarendon Press, 1977; 427–437.
Smith KJ. Conduction properties of central demyelinated and remyelinated axons, and their relation to symptom production in demyelinating disorders. Eye (Lond) 1994;8:224–237.
Leocani L, Guerrieri S, Comi G. Visual evoked potentials as a biomarker in multiple sclerosis and associated optic neuritis. J Neuroophthalmol 2018;38:350–357.
Fukutake T, Kuwabara S, Kaneko M, Kojima S, Hattori T. Sensory impairments in spinal multiple sclerosis: a combined clinical, magnetic resonance imaging and somatosensory evoked potential study. Clin Neurol Neurosurg 1998;100:199–204.
Leocani L, Martinelli V, Natali-Sora MG, Rovaris M, Comi G. Somatosensory evoked potentials and sensory involvement in multiple sclerosis: comparison with clinical findings and quantitative sensory tests. Mult Scler 2003;9:275–279.
Capone F, Capone G, Motolese F, et al. Spinal cord dysfunction contributes to balance impairment in multiple sclerosis patients. Clin Neurol Neurosurg 2019;184:105451.
Kalkers NF, Strijers RL, Jasperse MM, et al. Motor evoked potential: a reliable and objective measure to document the functional consequences of multiple sclerosis? Relation to disability and MRI. Clin Neurophysiol 2007;118:1332–1340.
Hardmeier M, Leocani L, Fuhr P. A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS. Mult Scler 2017;23:1309–1319.
O'Connor P, Marchetti P, Lee L, Perera M. Evoked potential abnormality scores are a useful measure of disease burden in relapsing-remitting multiple sclerosis. Ann Neurol 1998;44:404–407.
Fuhr P, Borggrefe-Chappuis A, Schindler C, Kappos L. Visual and motor evoked potentials in the course of multiple sclerosis. Brain 2001;124:2162–2168.
Schlaeger R, D'Souza M, Schindler C, Grize L, Kappos L, Fuhr P. Prediction of MS disability by multimodal evoked potentials: investigation during relapse or in the relapse-free interval? Clin Neurophysiol 2014;125:1889–1892.
Pelayo R, Montalban X, Minoves T, et al. Do multimodal evoked potentials add information to MRI in clinically isolated syndromes? Mult Scler 2010;16:55–61.
London F, Sankari SE, van Pesch V. Early disturbances in multimodal evoked potentials as a prognostic factor for long-term disability in relapsing-remitting multiple sclerosis patients. Clin Neurophysiol 2017;128:561–569.
Leocani L, Rovaris M, Boneschi FM, et al. Multimodal evoked potentials to assess the evolution of multiple sclerosis: a longitudinal study. J Neurol Neurosurg Psychiatry 2006;77:1030–1035.
Jung P, Beyerle A, Ziemann U. Multimodal evoked potentials measure and predict disability progression in early relapsing-remitting multiple sclerosis. Mult Scler 2008;14:553–556.
Schlaeger R, D'Souza M, Schindler C, Grize L, Kappos L, Fuhr P. Electrophysiological markers and predictors of the disease course in primary progressive multiple sclerosis. Mult Scler 2014;20:51–56.
Schlaeger R, D'Souza M, Schindler C, Grize L, Kappos L, Fuhr P. Combined evoked potentials as markers and predictors of disability in early multiple sclerosis. Clin Neurophysiol 2012;123:406–410.
Canham LJ, Kane N, Oware A, et al. Multimodal neurophysiological evaluation of primary progressive multiple sclerosis—an increasingly valid biomarker, with limits. Mult Scler Relat Disord 2015;4:607–613.
Schlaeger R, Hardmeier M, D'Souza M, et al. Monitoring multiple sclerosis by multimodal evoked potentials: numerically versus ordinally scaled scoring systems. Clin Neurophysiol 2016;127:1864–1871.
Magnano I, Pes GM, Pilurzi G, et al. Exploring brainstem function in multiple sclerosis by combining brainstem reflexes, evoked potentials, clinical and MRI investigations. Clin Neurophysiol 2014;125:2286–2296.
Magnano I, Pes GM, Cabboi MP, et al. Comparison of brainstem reflex recordings and evoked potentials with clinical and MRI data to assess brainstem dysfunction in multiple sclerosis: a short-term follow-up. Neurol Sci 2016; 37: 1457–1465.
Hardmeier M, Jacques F, Albrecht P, et al. Multicentre assessment of motor and sensory evoked potentials in multiple sclerosis: reliability and implications for clinical trials. Mult Scler J Exp Transl Clin 2019;5:2055217319844796.
Tobimatsu S, Celesia GG. Studies of human visual pathophysiology with visual evoked potentials. Clin Neurophysiol 2006;117:1414–1433.
Costello F. The afferent visual pathway: designing a structural-functional paradigm of multiple sclerosis. ISRN Neurol 2013;2013:134858.
Papadopoulou A, Gaetano L, Pfister A, et al. Damage of the lateral geniculate nucleus in MS: assessing the missing node of the visual pathway. Neurology 2019;92:e2240–e2249.
Raz N, Dotan S, Chokron S, Ben-Hur T, Levin N. Demyelination affects temporal aspects of perception: an optic neuritis study. Ann Neurol 2012;71:531–538.
Raz N, Chokron S, Ben-Hur T, Levin N. Temporal reorganization to overcome monocular demyelination. Neurology 2013;81:702–709.
Jenkins TM, Toosy AT, Ciccarelli O, et al. Neuroplasticity predicts outcome of optic neuritis independent of tissue damage. Ann Neurol 2010;67:99–113.
Benoliel T, Raz N, Ben-Hur T, Levin N. Cortical functional modifications following optic neuritis. Mult Scler 2017;23:220–227.
Husain AM, Hayes S, Young M, Shah D. Visual evoked potentials with CRT and LCD monitors: when newer is not better. Neurology 2009;72:162–164.
Narayanan D, Cheng H, Tang RA, Frishman LJ. Reproducibility of multifocal visual evoked potential and traditional visual evoked potential in normal and multiple sclerosis eyes. Doc Ophthalmol 2015;130:31–41.
Hess CW, Mills KR, Murray NM. Responses in small hand muscles from magnetic stimulation of the human brain. J Physiol 1987;388:397–419.
Di Lazzaro V, Ziemann U, Lemon RN. State of the art: physiology of transcranial motor cortex stimulation. Brain Stimul 2008;1:345–362.
Chen R, Cros D, Curra A, et al. The clinical diagnostic utility of transcranial magnetic stimulation: report of an IFCN committee. Clin Neurophysiol 2008;119:504–532.
Groppa S, Oliviero A, Eisen A, et al. A practical guide to diagnostic transcranial magnetic stimulation: report of an IFCN committee. Clin Neurophysiol 2012;123:858–882.
Brown KE, Lohse KR, Mayer IMS, et al. The reliability of commonly used electrophysiology measures. Brain Stimul 2017;10:1102–1111.
Heidari M, Radcliff AB, McLellan GJ, et al. Evoked potentials as a biomarker of remyelination. Proc Natl Acad Sci U S A 2019;116:27074–27083.
Farley BJ, Morozova E, Dion J, et al. Evoked potentials as a translatable biomarker to track functional remyelination. Mol Cell Neurosci 2019 ;99:103393.
Brusa A, Jones SJ, Plant GT. Long-term remyelination after optic neuritis: a 2-year visual evoked potential and psychophysical serial study. Brain 2001;124:468–479.
Klistorner A, Arvind H, Garrick R, Yiannikas C, Paine M, Graham SL. Remyelination of optic nerve lesions: spatial and temporal factors. Mult Scler 2010;16:786–795.
Tsakiri A, Kallenbach K, Fuglø D, Wanscher B, Larsson H, Frederiksen J. Simvastatin improves final visual outcome in acute optic neuritis: a randomized study. Mult Scler 2012;18:72–81.
Klistorner A, Garrick R, Barnett MH, et al. Axonal loss in non-optic neuritis eyes of patients with multiple sclerosis linked to delayed visual evoked potential. Neurology 2013;80:242–245.
Cadavid D, Balcer L, Galetta S, et al. RENEW study investigators. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2017;16:189–199.
Green AJ, Gelfand JM, Cree BA, et al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet 2017;390:2481–2489.
Meuth SG, Bittner S, Seiler C, Göbel K, Wiendl H. Natalizumab restores evoked potential abnormalities in patients with relapsing-remitting multiple sclerosis. Mult Scler 2011;17:198–203.
Iodice R, Carotenuto A, Dubbioso R, Cerillo I, Santoro L, Manganelli F. Multimodal evoked potentials follow up in multiple sclerosis patients under fingolimod therapy. J Neurol Sci 2016;365:143–146.
Waxman SG. Clinical course and electrophysiology of multiple sclerosis. In: Waxman SG, ed. Advances in neurology. Functional recovery in neurological disease. Vol. 47. New York: Raven Press, 1988; 157–84.
Waxman SG. Axonal dysfunction in chronic multiple sclerosis: meltdown in the membrane. Ann Neurol 2008;63:411–413.
Wegner C, Esiri MM, Chance SA, Palace J, Matthews PM. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology 2006;67:960–967.
Young EA, Fowler CD, Kidd GJ, et al. Imaging correlates of decreased axonal Na+/K+ ATPase in chronic multiple sclerosis lesions. Ann Neurol 2008;63:428–435.
Geurts JJ, Calabrese M, Fisher E, Rudick RA. Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol 2012;11:1082–1092.
Frohman EM, Costello F, Stüve O, et al. Modeling axonal degeneration within the anterior visual system: implications for demonstrating neuroprotection in multiple sclerosis. Arch Neurol 2008;65:26–35.
Balcer LJ, Miller DH, Reingold SC, Cohen JA. Vision and vision-related outcome measures in multiple sclerosis. Brain 2015;138:11–27.
Aktas O, Albrecht P, Hartung HP. Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis: update on current trials and perspectives. Curr Opin Neurol 2016;29:199–204.
Connick P, Kolappan M, Crawley C, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol 2012;11:150–156.
Frischer JM, Weigand SD, Guo Y, et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol 2015;78:710–721.
Patrikios P, Stadelmann C, Kutzelnigg A, et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006;129:3165–3172.
Harlow DE, Honce JM, Miravalle AA. Remyelination therapy in multiple sclerosis. Front Neurol 2015;6:257.
Schlaeger R, Papinutto N, Zhu AH, et al. Association between thoracic spinal cord gray matter atrophy and disability in multiple sclerosis. JAMA Neurol 2015;72:897–904.
Rocca MA, Battaglini M, Benedict RH, et al. Brain MRI atrophy quantification in MS: from methods to clinical application. Neurology 2017;88:403–413.
Barro C, Leocani L, Leppert D, Comi G, Kappos L, Kuhle J. Fluid biomarker and electrophysiological outcome measures for progressive MS trials. Mult Scler 2017;23:1600–1613.
Pisa M, Chieffo R, Giordano A, et al. Upper limb motor evoked potentials as outcome measure in progressive multiple sclerosis. Clin Neurophysiol 2020;131:401–405.
Rice CM, Mallam EA, Whone AL, et al. Safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis. Clin Pharmacol Ther 2010;87:679–685.
Kallmann BA, Fackelmann S, Toyka KV, Rieckmann P, Reiners K. Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis. Mult Scler 2006;12:58–65.
Invernizzi P, Bertolasi L, Bianchi MR, Turatti M, Gajofatto A, Benedetti MD. Prognostic value of multimodal evoked potentials in multiple sclerosis: the EP score. J Neurol 2011;258:1933–1939.
Margaritella N, Mendozzi L, et al. Sensory evoked potentials to predict short-term progression of disability in multiple sclerosis. Neurol Sci 2012;33:887–892.
Ramanathan S, Lenton K, Burke T, et al. The utility of multimodal evoked potentials in multiple sclerosis prognostication. J Clin Neurosci 2013;20:1576–1581.
Giffroy X, Maes N, Albert A, Maquet P, Crielaard JM, Dive D. Multimodal evoked potentials for functional quantification and prognosis in multiple sclerosis. BMC Neurol 2016;16:83.
Giffroy X, Maes N, Albert A, Maquet P, Crielaard JM, Dive D. Do evoked potentials contribute to the functional follow-up and clinical prognosis of multiple sclerosis? Acta Neurol Belg 2017;117:53–59.